Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
2003-05-19
2008-11-11
Kosar, Andrew D (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C514S009100, C514S011400, C530S332000, C530S333000, C530S345000
Reexamination Certificate
active
07449544
ABSTRACT:
The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.
REFERENCES:
patent: 4536397 (1985-08-01), Okumura et al.
patent: 4639434 (1987-01-01), Wenger et al.
patent: 5028588 (1991-07-01), Hoffman et al.
patent: 5240910 (1993-08-01), Lam et al.
patent: 5780221 (1998-07-01), Schumacher et al.
patent: 5811512 (1998-09-01), Hirschmann et al.
patent: 5837684 (1998-11-01), Orning et al.
patent: 5916872 (1999-06-01), Chang et al.
patent: 5962408 (1999-10-01), Orning et al.
patent: 6261569 (2001-07-01), Comis et al.
patent: 2002/0142966 (2002-10-01), Bair et al.
patent: 2003/0036628 (2003-02-01), Zheleva et al.
patent: 2004/0053849 (2004-03-01), Bair et al.
patent: 2004/0077549 (2004-04-01), Bair et al.
patent: 2005/0153894 (2005-07-01), Zheleva et al.
patent: 9928323.6 (1999-11-01), None
patent: WO-96/14334 (1996-05-01), None
patent: WO-96/35715 (1996-11-01), None
patent: WO-97/42222 (1997-11-01), None
Adams, Peter D., et al., “Identification of Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors,”Molecular and Cellular Biology, vol. 16(12):6623-6633 (1996).
Adams, Peter D., et al., “Retinoblastoma Protein Contains a C-terminal Motif That Targets It for a Phosphorylation by Cyclin-cdk Complexes,”Molecular and Cellular Biology, vol. 19(2):1068-1080 (1999).
Ball, Kathryn L., et al., “Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1,”Current Biology, vol. 7:71-80 (1996).
Bonfanti, Marina, et al., “p21WAF1-derived Peptides Linked to an Internalization Peptide Inhibit Human Cancer Cell Growth,”Cancer Research, vol. 57:1442-1446 (1997).
Brown, Nick R., et al., “The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases,”Nature Cell Biology, vol. 1:438-443 (1999).
Chen, Junjie, et al., “Cyclin-Binding Motifs Are Essential for the Function of p21CIP1,”Molecular and Cellular Biology, vol. 16(9):4673-4682 (1996).
Chen, Ying-Nan P., et al., “Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists,”Proc. Natl. Acad. Sci. USA, vol. 96:4325-4329 (1999).
Lin, Jiayuh, et al., Analysis of Wild-Type and Mutant p21WAF-1Gene Activities,Molecular and Cellular Biology, vol. 16(4):1786-1793 (1996).
Mutoh, Masato, et al., “A p21Wafl/Cip1Carboxyl-terminal Peptide Exhibited Cyclin-dependent Kinase-inhibitory Activity and Cytotoxicity When Introduced into Human Cells,”Cancer Research, vol. 59:3480-3488 (1999).
Pin, Sokhom S., et al., “Analysis of Protein-Peptide Interaction by a Miniaturized Fluorescence Polarization Assay Using Cyclin-Dependent Kinase 2/Cyclin E as a Model System,”Analytical Biochemistry, vol. 275:156-161 (1999).
Russo, Alicia A., et al., “Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex,” Nature, vol. 382:325-331 (1996).
Warbick, E., et al., “PCNA binding proteins in Drosophilia melanogaster: the analysis of a conserved PCNA binding domain,” Nucleic Acids Research, 26(17):3925-3932 (1998).
Database PIR—73, ACS 39358, Feb. 25, 1994.
Database SwissProt—40, AC P38936, Dec. 15, 1995.
Database SPTREMBL—21, AC Q14010, Nov. 1, 1996.
Database PIR—73, AC I54380, Jul. 2, 1996.
Database SwissProt—40, AC O19002, Dec. 15, 1998.
Andrews Martin J. I.
Atkinson Gail E.
Chan Weng C.
Fischer Peter Martin
McInnes Campbell
Cyclacel Limited
DeConti, Jr. Giulio A.
Kanik Cynthia L.
Kosar Andrew D
Lahive & Cockfield LLP
LandOfFree
p21 peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with p21 peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and p21 peptides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4032023